Methods	Allocation: randomised. Blindness: double. Duration: four weeks.
Participants	Diagnosis:(ICD-9) acute schizophrenia, disorganised, catatonic, paranoid, unspecified type. Schizoaffective psychosis, schizodominant type. N=59. Age: 19-65 years. Gender: 31 M, 28 F. Setting: not reported. History: duration ill not reported, age at onset not reported
Interventions	Clozapine: fixed dose: 400 mg/day. N=20. Risperidone: fixed dose: 4 mg/day. N=20. Risperidone: fixed dose: 8 mg/day. N=19.
Outcomes	Leaving the study early: any reason, adverse events, inefficacy. Global state: CGI. Mental state: BPRS total score, BPRS subscore. Adverse effects: at least one adverse effect, cardiac effects (pre terminal negative T-wave), extrapyramidal side-effects (extrapyramidal symptoms, use ofantiparkinson medication, Simpson-Angus Scale), sedation. Unable to use: White blood cell count: agranulocytosis (no data).
Notes
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Quote: “This is a randomised, double blind study..” Comment: Incomplete information.
Allocation concealment?	No	No information. Probably not done.
Blinding? All outcomes	Yes	Quote: “This is a randomised, double blind study..” Tablets were identical appearance. Comment: Probably done. The success of blinding was not evaluated
Incomplete outcome data addressed? All outcomes	Yes	6/20 missing from clozapine, 13/19 from risperidone 8 mg and 9/20 from risperi-done 4 mg. Intention to treat analyses and LOCF
Free of selective reporting?	No	There was incomplete information about some adverse events as body weight, blood pressure, ECG Adverse events considered only the most frequent spontaneously reported adverse experience
Free of other bias?	Yes	Review authors have not found other sources of bias.